^
    Back
    Association details:
    Biomarker:G0S2 overexpression
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    AACR 2020
    Title:

    Abstract 648: Role of G0S2 in chronic myeloid leukemia and TKI resistance

    Published date:
    06/23/2020
    Excerpt:
    Retrospective analysis of survival data for patients whose samples were evaluated in a microarray revealed that high G0S2 expression (>50%) correlated with a longer overall survival (n=30 responders, n=16 non-responders, p=0.036).
    DOI:
    10.1158/1538-7445.AM2020-648